Published in BMC Cancer
Background The growth factor progranulin has been implicated in numerous biological processes such as wound healing, inflammation and progressive tumorigenesis. Both progranulin and its receptor sortilin are known to be highly expressed in subgroups of breast cancer and have been associated with various clinical properties including tamoxifen resis...
Published in Journal of Hematology & Oncology
Histone methylation is a key posttranslational modification of chromatin, and its dysregulation affects a wide array of nuclear activities including the maintenance of genome integrity, transcriptional regulation, and epigenetic inheritance. Variations in the pattern of histone methylation influence both physiological and pathological events. Lysin...
Published in Biology Open
Summary: A discussion of the role and regulation of myosin super relaxation in biology, evolution, human disease, and cardiac therapeutics.
Published in Current Treatment Options in Oncology
With a growing understanding of the biologic drivers of different thyroid cancers, there is an ongoing revolution in the treatment of aggressive and advanced disease variants. This includes matching patients with specific point mutations or gene fusions to targeted therapies (e.g., selective RET inhibitors), delineating patients who are likely to r...
Published in Medical Oncology
Biliary tract cancer is an uncommon cancer in developed countries. In localized stages, surgery is the cornerstone of treatment with curative purpose. Conversely in advanced stages, chemotherapy with platinum–gemcitabine combination is the standard of care. Biliary tract cancers are a biologically heterogeneous group of malignancies, which perhaps ...
Published in European urology oncology
Immuno-oncology (IO) therapies have changed the treatment standards of metastatic renal cell carcinoma (mRCC). However, the effectiveness of targeted therapy following discontinuation of IO therapy in real-world settings has not been well studied. To describe treatment sequence and assess clinical effectiveness of targeted therapy for mRCC patients...
Published in Der Urologe. Ausg. A
Mit jährlich etwa 30.000 Neuerkrankungen ist das Harnblasenkarzinom (BC) eines der häufigsten Karzinome in Deutschland, und die Inzidenz steigt mit dem Alter. Das Urothelkarzinom stellt die häufigste histologische Variante des BC in Mitteleuropa dar. Das nichtmuskelinvasive Karzinom der Harnblase kann endourologisch reseziert und über eine intraves...
Published in World journal of urology
To compare survival outcomes of metastatic patients harbouring either papillary (pRCC) or clear-cell (ccRCC) renal cell carcinoma in overall population and according to treatment modality. Within the Surveillance, Epidemiology and End Results database (2006-2015), we identified 6800 patients (585 papillary and 6215 clear-cell) with metastatic RCC. ...
Published in Seminars in cancer biology
Nanotechnology has been the latest approach for diagnosis and treatment for cancer, which opens up a new alternative therapeutic drug delivery option to treat disease. Nanoparticles (NPs) display a broad role in cancer diagnosis and has various advantages over the other conventional chemotherapeutic drug delivery. NPs possess more specific and effi...
Published in Breast Cancer Research
BackgroundThere is currently no clinical trial data regarding the efficacy of everolimus exemestane (EE) following prior treatment with CDK4/6 inhibitors (CDK4/6i). This study assesses the use and efficacy of everolimus exemestane in patients with metastatic HR+ HER2− breast cancer previously treated with endocrine therapy (ET) or endocrine therapy...
